-
Mashup Score: 0Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC - 3 hour(s) ago
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC - 4 hour(s) ago
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma - 7 hour(s) ago
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Overview of Graft-vs-Host Disease (GvHD) - 9 hour(s) ago
Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15NSCLC Clinical Case Simulations for Practicing Oncologists - 10 hour(s) ago
Welcome to our interactive training module. Please select from below to
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer - 12 hour(s) ago
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Adding tivumecirnon to pembrolizumab elicited responses and was well tolerated in patients with recurrent or metastatic HNSCC who were previously exposed to a checkpoint inhibitor, particularly those with HPV–positive disease. @DukeCancer #hnscc #oncology https://t.co/XXHQHIIMJ4 https://t.co/0dsArKaavC